| Dear Voornaam, Happy new year and I hope you all had a restful holiday period. With 2022 finally here, there's much to be excited about in cancer research. A huge congratulations to all scientists recognised in the 2022 New Year Honours list for their stellar contributions to science and particularly those closely related to Cancer Research UK (CRUK): Professor Nick Lemoine and Sir Paul Nurse. In the coming months, we'll be publishing a refreshed research strategy, expanding our vision and ambition in cancer prevention research, and launching new ways in which we'll work in the therapeutic and commercial space. We're opening the DETERMINE trial in partnership with the University of Manchester and Roche. Its a multi-drug, precision medicine platform trial for adults and children with rare cancers. What makes DETERMINE so exciting is that well be able to potentially fast track the approval of any promising drugs, opening the door to treatments for patients who have historically been left with limited options. In the coming year, we also hope to see more of our researchers utilising our cutting-edge CRISPR technology at the Functional Genomics Centre. Our centre based in Cambridge is applying CRISPR screening in discovery biology research and helping to guide the way to new and better cancer medicines.
I look forward to another year of working collaboratively with you all to support your ideas, help our community thrive and bring impact to people affected by cancer through the development of life-saving research. Kind regards, Iain Foulkes Executive Director, Research & Innovation Cancer Research UK |
|
|---|
|
|---|
|
|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
CRUK BRAIN TUMOUR CONFERENCE 4 WEEKS LEFT TO SUBMIT AN ABSTRACT The CRUK Brain Tumour Conference will take place in London on 1618 May 2022, with an agenda designed to spark fresh ideas, lively debate and new opportunities for collaborative research. All attendees are invited to submit a poster abstract based on any of the session themes. Dont miss out on the opportunity to showcase your work alongside our stellar line-up of leading international scientists. Abstract submission deadline: 11 February |
|
|---|
| WHY OUR CHIEF CLINICIAN WENT TO A CLIMATE CHANGE SUMMIT There's a growing number of lung cancer cases in patients who have never smoked. Our chief clinician Professor Charles Swanton attended COP26 last year to shed light on the concerning links between pollution and lung cancer in never smokers. We spoke to Charles and his lab about what we know, what we need to know and how well get there. |
|
|---|
|
|---|
|
|
| | DETERMINED TO TACKLE RARE CANCERS We've partnered with The University of Manchester and Roche to run the DETERMINE trial a multi-drug, precision medicine platform trial for adults and children with rare cancers who have run out of other treatment options. It aims to find out whether existing drugs could also benefit patients with rare cancer types that the drug isnt currently licensed for. Our Centre for Drug Development will sponsor and manage the trial, led by chief investigator Dr Matthew Krebs from the University of Manchester and the Christie NHS Foundation Trust. DETERMINE is set to open to recruitment nationwide in early summer 2022. |
|
|---|
|
|---|
|
|
| | DELIVERING ON THE PROMISE OF EARLY DETECTION WITH LIQUID BIOPSIES In The British Journal of Cancers Special Issue on Liquid Biopsies, David Crosby, our Head of Prevention and Early Detection Research discusses the huge potential of liquid biopsy approaches for cancer early detection. David highlights how CRUK-funded research is driving progress in this area but acknowledges that there are still numerous challenges to overcome. Along with other early detection approaches, research into liquid biopsies is a key part of our strategy and we welcome more consideration not only into further technological development, but how such tests will be translated and trialled in real-world clinical settings. |
|
|---|
|
|---|
|
|
CHANGES TO OUR OPEN ACCESS POLICY As of 1 January, weve taken the steps we previously announced to make our research open access. This means all research we fund, in whole or in part, should now be made open access immediately on publication.
Making published research available in an open and unrestricted way maximises its impact by facilitating rapid sharing of knowledge, promoting innovation and ultimately ensuring that patients can access better treatments sooner. If you have questions about these changes, check out our helpful Q&A on the site or get in touch with [email protected]. |
|
|---|
| NOTIFY US OF YOUR MANUSCRIPT SUBMISSIONS Have you recently submitted a paper for publication? If so, we'd love to hear about it. Knowing about the work we fund helps us to communicate with our supporters about the amazing work their donations help fund. Complete this short form to let us know about your pending publications. We'll treat all information you provide as strictly confidential, and we wont use it without consulting you first. |
|
|---|
|
|---|
|
|
RESEARCHFISH SUBMISSION PERIOD OPENING SOON In February, well be asking the majority of CRUK awards holders, institute group leaders and students to submit their research outputs to Researchfish. The submission period for this year opens on 7 February and closes on 17 March. If a submission is needed from you, well be in touch via email in the coming weeks with more details. We use Researchfish to capture the outputs and impact of the research we fund. It helps inform our strategies to support world-class research and communicate its impact to our supporters, the government and the public. |
|
|---|
| HOST A SUMMER PLACEMENT STUDENT IN THE IN2RESEARCH PROGRAMME Are you a London-based cancer researcher? In2scienceUK are looking for cancer research labs in London to host 8-week summer placement students for their In2research programme. Being a placement host is a fantastic opportunity to contribute towards making a career in cancer research more accessible and build a more diverse and inclusive cancer research community. Host application deadline: 19 January For more information, get in touch with the In2scienceUK team at [email protected] |
|
|---|
|
|---|
|
|
CALLS FOR UK'S CONTINUING ACCESS TO EUROPEAN RESEARCH FUNDING SCHEME The UK's membership to Horizon Europe ensures continued collaboration between scientists in the UK and the EU, which is why we've added our voice to recent calls for the UK to formalise its full Horizon Europe association, including the EUs Cancer Mission. Last month, our chief executive officer Michelle Mitchell signed a joint letter to urge the government not to abandon their vital commitment to Horizon Europe. |
|
|---|
| THE BENEFITS, ETHICS AND SHEER FUN OF COMMUNICATING YOUR RESEARCH The Science Museum recently opened the doors to its latest exhibition which focuses on how cancer is treated, prevented and detected. Developed with CRUK as expert partners, exhibitions like this help to bridge the gap between researchers and the public. We spoke to science communication experts Hana Dethlefsen from the Crick and Frances Balkwill from Barts Cancer Institute about communicating your research. |
|
|---|
|
|---|
|
|
| | KEEP UP TO DATE WITH THE LATEST CANCER RESEARCH EVENTS Events are a brilliant way to learn from others, expand your network and stay up to date with the latest in your field and in other areas of cancer. We encourage our community to attend, whether online or in-person, various events happening across the cancer research space. Sign up to our events newsletter to hear more about the various events happening this year. |
|
|---|
|
|---|
|
|
| | | Register your interest 18 October 2022 |
|
|---|
|
|---|
|
|
| Been forwarded this email? Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
